How much cash does Climb Bio, Inc. generate?

Climb Bio, Inc. (CLYM) generated -$53.3M in operating cash flow over the trailing twelve months.

What is Climb Bio, Inc.'s free cash flow?

After $109.0K of capital expenditures, Climb Bio, Inc.'s free cash flow was -$41.0M over the trailing twelve months.

Where does Climb Bio, Inc.'s cash flow data come from?

Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Climb Bio, Inc. CLYM Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$52.79M+43.2%	-$59.85M+19.0%	-$50.75M+26.6%	-$46.76M+27.2%	-$92.98M-540%
Depreciation and amortization	$135K—	$97K—	$67K—	$38K—	——
Stock-based compensation	$7.64M+7.4%	$8.05M+44.9%	$8.67M+69.9%	$7.62M+169%	$7.11M+129%
Change in accounts payable	$83K—	$1.56M—	——	——	——
Change in accrued liabilities	——	——	——	——	$4.23M—
Change in other assets	$1.5M—	$1.51M—	$1.73M—	——	——
Change in other liabilities	——	——	——	——	——
Change in operating lease liabilities	$40K+115%	$43K+113%	$46K+111%	$63K+113%	-$262K+43.2%
Net cash from operating activities	-$53.3M-82.7%	-$54.36M-249%	-$44.24M-303%	-$39.66M—	-$29.18M—
Capital expenditures	——	——	——	——	——
Acquisitions, net of cash acquired	——	——	——	——	——
Net cash from investing activities	——	——	——	——	-$177.59M-326%
Proceeds from issuance of common stock	$70K-99.4%	$65K-99.4%	$41K-99.6%	$2.31M-75.6%	$10.96M+1,182%
Net cash from financing activities	-$16K-100%	-$21K-100%	$41K-100.0%	$2.31M-98.2%	$130.71M+15,188%
Effect of exchange rate changes on cash	$24K—	$0—	——	——	——
Net increase (decrease) in cash	——	——	——	-$200.46M-201%	-$76.01M-208%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.91M+40.1%	$2.27M+200%	$2.29M+296%	$1.93M+66.4%	$1.36M-28.4%
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——	——
Accrued expenses and other liabilities	——	——	——	——	——
Operating lease liabilities	$40K+115%	$43K+113%	$46K+111%	$63K+113%	-$262K+43.2%
Prepaid expenses and other current assets	$1.78M—	$816K—	-$403K—	——	——
Payments Of Stock Issuance Costs	——	$86K—	$64.5K—	$43K—	$21.5K—
Common stock issuance for private placement	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	$24K—	$0—	——	——	——
Increase Decrease In Operating Lease Liability	$40K+115%	$43K+113%	$46K+111%	$63K+113%	-$262K+43.2%
Operating Lease Expense	$220K+28.7%	$201K-8.6%	$177K-35.4%	$130K-63.0%	$171K-53.9%
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Cash Paid For Leases Included In Operating Cash Outflows	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Climb Bio, Inc. generate?: Climb Bio, Inc. (CLYM) generated -$53.3M in operating cash flow over the trailing twelve months.
What is Climb Bio, Inc.'s free cash flow?: After $109.0K of capital expenditures, Climb Bio, Inc.'s free cash flow was -$41.0M over the trailing twelve months.
Where does Climb Bio, Inc.'s cash flow data come from?: Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.